Spots Global Cancer Trial Database for Registry Platform Gastric/Esophageal Cancer (SAPHIR)

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Registry Platform Gastric/Esophageal Cancer (SAPHIR)

Official Title: Clinical Research Platform For Molecular Testing, Treatment, Quality Of Life And Outcome Of Patients With Esophageal, Gastric Or Gastroesophageal Junction Cancer Requiring Palliative Systemic Therapy

Study ID: NCT04290806

Conditions

Esophageal Squamous Cell Carcinoma

Gastric Adenocarcinoma

Gastroesophageal Junction Adenocarcinoma

Esophageal Adenocarcinoma

Interventions

Routine care as per site standard

Study Description

Brief Summary: The registry aims to collect and analyse information on the antineoplastic treatment of patients with metastatic esophageal, gastric or gastroesophageal junction cancer, treated in palliative intention in daily routine practice in Germany.

Detailed Description: SAPHIR is a national, observational, prospective, longitudinal, multicenter cohort study (tumor registry platform) with the purpose to record information on the antineoplastic treatment of metastatic esophageal, gastric or gastroesophageal junction Cancer in Germany. The registry will follow patients for up to two years. It will identify common therapeutic sequences and changes in the treatment of the disease. At inclusion, data in patient characteristics, comorbidities, tumor characteristics and previous treatments are collected. During the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented. Health-related quality of life (HRQoL) will be evaluated for up to two years.